Live Breaking News & Updates on Xpected Us21077p1084

Stay updated with breaking news from Xpected us21077p1084. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones

CTIM-76 nominated as Claudin 6 x CD3 bispecific antibody clinical candidate Encouraging endometrial and breast cancer data in ongoing ONA-XR Phase 2 trials, with additional data updates expected in. | January 4, 2023 ....

United States , San Antonio , Martin Lehr , Gina Cestari , Company Nasdaq , Menarini Group , Context Therapeutics Inc , Exchange Commission , San Antonio Breast Cancer Symposium , Advanced Endometrial , Elacestrant Versus Standard Endocrine Therapy , Estrogen Receptor Positive , Human Epidermal Growth Factor Receptor , Negative Advanced Breast Cancer , Results From , Randomized Phase , Private Securities Litigation Reform Act , Context Therapeutics Inc Stock Exchange , Press Release , Xpected Us21077p1084 ,